CGEN

Compugen Ltd

2.09

Nov 11 • 3:59 PM ET 0.00 (0.00%)

2.09

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology Israel Micro NASD

Nov 09, 10:42 AMCompugen extends cash runway into 2029 and highlights major 2027 clinical data catalysts after Q3 2026 earnings beat

Peers: MGNX ADAG AGEN ALXO CMPX CUE RCUS ABCL AZN GILD

| Held by: SPDW AVDV GWX QQQS AVSD

Scroll to Statements

Index	-
Market Cap	197.98M
Enterprise Value	83.24M
Income	36.37M
Sales	75.93M
Book/sh	0.88
Cash/sh	1.24
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	75
IPO	Aug 11, 2000

P/E	5.44
Forward P/E	-
PEG	-
P/S	2.61
P/B	2.37
P/C	1.68
P/FCF	-
EV/EBITDA	-
EV/Sales	1.10
Quick Ratio	4.90
Current Ratio	4.90
Debt/Eq	0.03
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	0.38
EPS next Y	-0.27
EPS next Q	-0.05
EPS this Y	-172.11%
EPS next Y	0.00%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	113.28% 105.20%
EPS Y/Y TTM	229.14%
Sales Y/Y TTM	999.97%
EPS Q/Q	17.96%
Sales Q/Q	102.06%
Earnings	Nov 09 BMO
EPS/Sales Surpr.	25.19% 197.45%

Insider Own	0.37%
Insider Trans	-0.53%
Inst Own	15.11%
Inst Trans	-0.04%
ROA	31.99%
ROE	57.19%
ROIC	42.52%
Gross Margin	86.23%
Oper. Margin	41.28%
Profit Margin	47.90%
SMA20	3.81%
SMA50	-5.83%
SMA200	-8.83%
Trades

Shs Outstand	94.73M
Shs Float	94.37M
Short Float	2.68%
Short Ratio	10.38
Short Interest	2.53M
52W High	3.23 -35.39%
52W Low	1.43 46.15%
Volatility	6.13% 5.48%
ATR (14)	0.10
RSI (14)	50.68
Beta	2.80
Rel Volume	0.87
Avg Volume	243.51K
Volume	210,979

Perf Week	2.96%
Perf Month	5.56%
Perf Quarter	-13.28%
Perf Half Y	-26.67%
Perf YTD	36.60%
Perf Year	21.51%
Perf 3Y	262.22%
Perf 5Y	-70.81%
Perf 10Y	-68.57%
Recom	1.00
Target Price	4.80
Prev Close	2.09
Price	2.09
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$4.80

Implied Upside

+129.7%

Analysts12incl. previous ratings

Rating Distribution11 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 07, 2026	Initiated	LLake Street	Buy	$6	+187.1%
Jan 07, 2026	Initiated	HH.C. Wainwright	Buy	$4	+91.4%
Jan 13, 2025	Initiated	OOppenheimer	Outperform	$4	+91.4%
Aug 05, 2022	Downgrade	JJefferies	Buy → Hold	$2	-4.3%
May 26, 2020	Resumed	JJMP Securities	Mkt Outperform	$18	+761.2%
May 13, 2020	Initiated	SStifel	Buy	$19	+809.1%
May 07, 2020	Initiated	SSVB Leerink	Outperform
Apr 22, 2020	Initiated	RROTH Capital	Buy	$28	+1,239.7%
Mar 24, 2020	Initiated	SSunTrust	Buy	$16	+665.6%
Jan 16, 2020	Initiated	CCantor Fitzgerald	Overweight	$10	+378.5%
Mar 29, 2018	Initiated	OOppenheimer	Outperform
Feb 01, 2016	Resumed	OOppenheimer	Outperform
Oct 15, 2015	Initiated	FFBR Capital	Outperform	$14	+569.9%
Apr 23, 2015	Resumed	JJefferies	Buy	$11	+426.3%
Apr 21, 2015	Initiated	OOppenheimer	Outperform	$11	+426.3%
Feb 07, 2014	Initiated	MMLV & Co	Buy	$14	+569.9%
Dec 28, 2009	Reiterated	CCantor Fitzgerald	Buy	$5 → $12	+474.2%
Jul 29, 2009	Initiated	CCantor Fitzgerald	Buy	$6.50	+211.0%

Nov-10-26 07:00AM	Compugen to Present UnigenX Platform at the 18th Annual PEGS Europe Summit (PR Newswire)
Nov-09-26 10:47AM	Compugen Beats On Gilead-Driven Revenue, But The Quarter Matters Mainly As A Bridge To A Binary MAIA-Ovarian Readout (Earnings Whispers) +9.18%
07:06AM	Compugen: Q3 Earnings Snapshot (Associated Press)
07:00AM	Compugen Reports Third Quarter 2026 Results (PR Newswire)
Nov-03-26 07:00AM	Compugen to Participate in November Investor Conferences (PR Newswire)
11:01AM	Loading…
Nov-02-26 11:01AM	Compugen Heads Into Q3 Near Its Lows As Investors Await Clarity On MyOvarian And Gilead (Earnings Whispers)
Oct-26-26 07:00AM	Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026 (PR Newswire)
Oct-06-26 07:00AM	Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference (PR Newswire)
Sep-22-26 07:00AM	Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen Platform Update on October 5, 2026 (PR Newswire)
Sep-08-26 07:00AM	Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
Aug-26-26 07:00AM	TROPION-Urothelial04 Phase 3 Trial of Datroway Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer (Business Wire)
Aug-05-26 09:01PM	Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ... (GuruFocus.com)
Aug-03-26 07:03AM	Compugen: Q2 Earnings Snapshot (Associated Press)
07:00AM	Compugen Reports Second Quarter 2026 Results (PR Newswire)
Jul-31-26 09:20AM	Earnings To Watch: Compugen Ltd (CGEN) Reports Q2 2026 Result (GuruFocus.com)
07:00AM	Loading…
Jul-21-26 07:00AM	Compugen to Participate in BTIG Biotechnology Conference 2026 (PR Newswire) +6.41%
Jul-20-26 07:00AM	Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 (PR Newswire)
Jun-18-26 07:00AM	Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress (PR Newswire)
Jun-11-26 07:00AM	Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 (PR Newswire)
Jun-08-26 07:00AM	Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development (PR Newswire)
May-25-26 09:01PM	Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
May-18-26 08:35AM	Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN) (InvestorsHub)
07:58AM	Compugen: Q1 Earnings Snapshot (Associated Press)
07:00AM	Compugen Reports First Quarter 2026 Results (PR Newswire)
May-12-26 07:00AM	Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum (PR Newswire)
May-04-26 07:00AM	Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026 (PR Newswire)
Apr-09-26 07:00AM	Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference (PR Newswire) +8.30%
Mar-03-26 08:03PM	Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -11.11% +7.00%
Mar-02-26 08:15AM	Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates (Zacks) +24.31%
07:17AM	Compugen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Compugen Reports Fourth Quarter and Full Year 2025 Results (PR Newswire)
Feb-27-26 07:22AM	Compugen Ltd (CGEN) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-26-26 09:55AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-25-26 07:25PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates (Zacks)
Feb-19-26 05:35PM	Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.29%
07:00AM	Compugen to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-17-26 07:00AM	Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026 (PR Newswire)
Feb-12-26 07:00AM	Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors (PR Newswire)
Dec-17-25 07:00AM	Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million (PR Newswire)
Nov-12-25 10:01AM	Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-10-25 08:15AM	Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:16AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Third Quarter 2025 Results (PR Newswire)
Nov-07-25 07:24AM	Compugen Ltd (CGEN) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-06-25 06:55PM	Certara, Inc. (CERT) Q3 Earnings Surpass Estimates (Zacks)
Nov-04-25 07:00AM	Compugen to Participate in Stifel 2025 Healthcare Conference (PR Newswire) -6.94%
Nov-03-25 05:15PM	Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-27-25 07:00AM	Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 (PR Newswire)
Oct-13-25 07:00AM	Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 (PR Newswire) +21.08%
Oct-06-25 07:00AM	Compugen to Present at SITC 2025 (PR Newswire) +9.82%
Sep-08-25 07:00AM	Compugen to Present Research at the Single Cell Genomics 2025 Conference (PR Newswire)
Aug-28-25 07:00AM	Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-06-25 08:20AM	Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:19AM	Compugen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Second Quarter 2025 Results (PR Newswire)
Jul-28-25 07:00AM	Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025 (PR Newswire)
Jul-23-25 07:00AM	Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025 (PR Newswire)
Jul-21-25 07:00AM	Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer (PR Newswire)
Jun-24-25 02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks)
10:42AM	Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
10:38AM	XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? (Zacks)
08:54AM	Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
07:50AM	Graham (GHM) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
07:31AM	GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last? (Zacks)
04:41AM	Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength? (Zacks)
Jun-17-25 11:10AM	Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? (Zacks)
07:38AM	EchoStar (SATS) Moves 49.1% Higher: Will This Strength Last? (Zacks)
Jun-12-25 07:00AM	Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences (PR Newswire)
May-20-25 03:03AM	Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline (GuruFocus.com)
May-19-25 11:55AM	Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
10:53AM	Compugen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports First Quarter 2025 Results (PR Newswire)
May-15-25 05:30PM	Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-14-25 06:35PM	Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-13-25 07:00AM	Compugen Announces Leadership Transitions Effective September 2025 (PR Newswire)
May-12-25 05:25PM	Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates (Zacks)
May-08-25 05:35PM	McKesson (MCK) Tops Q4 Earnings Estimates (Zacks)
May-05-25 07:00AM	Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025 (PR Newswire) -7.43%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-26-25 07:00AM	Compugen to Participate in Multiple Virtual Investor Conferences in April 2025 (PR Newswire)
Mar-23-25 08:29AM	Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-05-25 02:04AM	Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) +7.74%
Mar-04-25 08:15AM	Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.18%
08:15AM	Compugen Reports Fourth Quarter and Full Year 2024 Results (PR Newswire)
07:22AM	Compugen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	/C O R R E C T I O N -- Compugen Ltd./ (PR Newswire)
Mar-03-25 07:00AM	Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference (PR Newswire) -5.73%
Feb-26-25 07:00AM	Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen with Ultima Genomics' Single Cell Genomics Sequencing Technology (PR Newswire)
Feb-18-25 07:00AM	Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025 (PR Newswire)
Feb-04-25 07:00AM	Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-08-25 07:00AM	Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors (PR Newswire)
Nov-27-24 07:00AM	Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies (PR Newswire) +5.92%
Nov-13-24 02:08AM	Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... (GuruFocus.com)
Nov-12-24 11:05AM	Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates (Zacks) -8.05%
09:56AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Third Quarter 2024 Results (PR Newswire)
Nov-11-24 07:00AM	Compugen to Participate in Stifel 2024 Healthcare Conference (PR Newswire)
Nov-05-24 09:00AM	Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Levine Zurit	SVP, Business Development	Jul 09 '26	Option Exercise	0.83	1,875	1,555	31,250	Jul 13 04:01 PM
Levine Zurit	SVP, Business Development	Jul 09 '26	Sale	2.50	1,875	4,688	29,375	Jul 13 04:01 PM
Levine Zurit	SVP, Business Development	Apr 24 '26	Option Exercise	1.15	2,000	2,300	31,375	Apr 27 04:03 PM
Levine Zurit	SVP, Business Development	Apr 24 '26	Sale	3.20	2,000	6,400	29,375	Apr 27 04:03 PM
Ophir Eran	President and CEO	Apr 24 '26	Option Exercise	0.83	5,000	4,146	16,375	Apr 27 04:02 PM
Ophir Eran	President and CEO	Apr 24 '26	Sale	3.20	5,000	16,000	11,375	Apr 27 04:02 PM
Ophir Eran	Officer	Apr 24 '26	Proposed Sale	2.92	5,000	14,600		Apr 27 06:52 AM
Levine Zurit	Officer	Apr 24 '26	Proposed Sale	2.92	4,000	11,680		Apr 27 06:40 AM
Ophir Eran	President and CEO	Apr 14 '26	Option Exercise	0.83	5,000	4,146	16,375	Apr 15 04:10 PM
Ophir Eran	President and CEO	Apr 14 '26	Sale	2.90	5,000	14,521	11,375	Apr 15 04:10 PM
Levine Zurit	SVP, Business Development	Apr 14 '26	Option Exercise	1.15	2,000	2,300	31,375	Apr 15 04:07 PM
Levine Zurit	SVP, Business Development	Apr 14 '26	Sale	2.80	2,000	5,600	29,375	Apr 15 04:07 PM
Ophir Eran	Officer	Apr 14 '26	Proposed Sale	2.76	5,000	13,800		Apr 15 06:38 AM
Levine Zurit	Officer	Apr 14 '26	Proposed Sale	2.76	2,000	5,520		Apr 15 06:16 AM
Levine Zurit	SVP, Business Development	Apr 10 '26	Option Exercise	1.03	3,125	3,233	32,500	Apr 13 04:04 PM
Levine Zurit	SVP, Business Development	Apr 10 '26	Sale	2.56	3,125	8,012	29,375	Apr 13 04:04 PM
Levine Zurit	Officer	Apr 10 '26	Proposed Sale	2.48	2,000	4,960		Apr 13 07:28 AM
Levine Zurit	SVP, Business Development	Apr 08 '26	Option Exercise	0.89	5,375	4,778	34,750	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 07 '26	Option Exercise	0.83	2,500	2,073	31,875	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 08 '26	Sale	2.42	5,375	13,008	29,375	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 07 '26	Sale	2.30	2,500	5,750	29,375	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 01 '26	Option Exercise	0.92	3,500	3,223	32,875	Apr 03 07:31 AM
Levine Zurit	SVP, Business Development	Apr 01 '26	Sale	2.20	3,500	7,700	29,375	Apr 03 07:31 AM
Ophir Eran	President and CEO	Apr 01 '26	Option Exercise	0.83	5,625	4,664	17,000	Apr 03 07:29 AM
Ophir Eran	President and CEO	Apr 01 '26	Sale	2.21	5,625	12,413	11,375	Apr 03 07:29 AM
Ophir Eran	Officer	Apr 01 '26	Proposed Sale	2.13	5,625	11,981		Apr 02 10:06 AM
Levine Zurit	SVP, Business Development	Mar 26 '26	Option Exercise	0.83	11,875	9,847	41,250	Mar 30 06:04 PM
Levine Zurit	SVP, Business Development	Mar 26 '26	Sale	2.04	11,875	24,187	29,375	Mar 30 06:04 PM
Levine Zurit	Officer	Mar 26 '26	Proposed Sale	2.06	24,375	50,212		Mar 26 10:42 AM

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Executive ChairDr. Anat Cohen-Dayag Ph.D.

CEODr. Eran Ophir Ph.D.

Chief Operating OfficerDr. Pierre Ferre Ph.D.

Senior Vice President of Business DevelopmentDr. Zurit Levine Ph.D.

Chief Medical OfficerMs. Michelle Mahler M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

CGEN

Compugen Ltd

Upgrade your Finviz experience

All the Features.
Half the Price.